Get notified of page updates
People with metastatic colorectal cancer that is MSI-High
Clinicaltrials.gov identifier:NCT04008030
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
People with metastatic colorectal cancer that is MSI-High
Clinicaltrials.gov identifier:NCT04008030
Glossary on
off
About the Study
NOTE: This study is no longer recruiting patients.
The purpose of this study is to compare the benefit of the combination of agents nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients who have High (MSI-H) or Mismatch Repair Deficient () colorectal cancer versus using nivolumab as a single therapy or chemotherapy.
This Study is Open To:
NOTE: This study is no longer recruiting patients.
This Study is NOT Open To:
NOTE: This study is no longer recruiting patients.